Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, 14004 Córdoba, Spain.
EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre, University of Granada, 18016 Granada, Spain.
Nutrients. 2022 Nov 6;14(21):4691. doi: 10.3390/nu14214691.
Parenteral nutrition (PN) is a life-saving therapy providing nutritional support in patients with digestive tract complications, particularly in preterm neonates due to their gut immaturity during the first postnatal weeks. Despite this, PN can also result in several gastrointestinal complications that are the cause or consequence of gut mucosal atrophy and gut microbiota dysbiosis, which may further aggravate gastrointestinal disorders. Consequently, the use of PN presents many unique challenges, notably in terms of the potential role of the gut microbiota on the functional and clinical outcomes associated with the long-term use of PN. In this review, we synthesize the current evidence on the effects of PN on gut microbiome in infants and children suffering from diverse gastrointestinal diseases, including necrotizing enterocolitis (NEC), short bowel syndrome (SBS) and subsequent intestinal failure, liver disease and inflammatory bowel disease (IBD). Moreover, we discuss the potential use of pre-, pro- and/or synbiotics as promising therapeutic strategies to reduce the risk of severe gastrointestinal disorders and mortality. The findings discussed here highlight the need for more well-designed studies, and harmonize the methods and its interpretation, which are critical to better understand the role of the gut microbiota in PN-related diseases and the development of efficient and personalized approaches based on pro- and/or prebiotics.
肠外营养(PN)是一种救命疗法,为患有消化道并发症的患者提供营养支持,特别是在早产儿中,因为他们在出生后的头几周内肠道尚未成熟。尽管如此,PN 也可能导致多种胃肠道并发症,这些并发症是肠道黏膜萎缩和肠道微生物群落失调的原因或结果,这可能进一步加重胃肠道疾病。因此,PN 的使用带来了许多独特的挑战,尤其是在肠道微生物群对与长期使用 PN 相关的功能和临床结果的潜在作用方面。在这篇综述中,我们综合了目前关于 PN 对患有各种胃肠道疾病的婴儿和儿童肠道微生物组影响的证据,包括坏死性小肠结肠炎(NEC)、短肠综合征(SBS)和随后的肠衰竭、肝病和炎症性肠病(IBD)。此外,我们还讨论了使用预、pro- 和/或合生菌作为有前途的治疗策略的可能性,以降低严重胃肠道疾病和死亡率的风险。这里讨论的结果强调了需要进行更多精心设计的研究,并协调方法及其解释,这对于更好地理解肠道微生物群在 PN 相关疾病中的作用以及基于 pro- 和/或合生菌开发有效和个性化的方法至关重要。